Navigating Deals and Licensing for Antibody Drug Conjugates
Antibody-drug conjugates ADCs are a promising class of cancer treatments with an accelerating number of U.S. Food and Drug Administration FDA.
Source: natlawreview.com
Immunogen Elahere News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Immunogen Elahere. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Immunogen Elahere Today - Breaking & Trending Today
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might have in store.
Source: cnbc.com
AbbVie to buy cancer drugmaker ImmunoGen for $10 billion as Humira faces heat
AbbVie will buy ImmunoGen for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to buy a developer of 'guided missile' cancer therapies…
Source: biztoc.com
In Proof-of-Concept NSCLC Trial, Mythic Hoping to Show Broad Utility of Antibody-Drug Conjugate
The firm has designed its lead candidate, MYTX-011, to treat NSCLC patients with high to low cMET-expressing tumor cells.
Source: precisionmedicineonline.com